Marloes van Dongen

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies.

Aurélien Marabelle, Philippe A. Cassier, Marwan Fakih et al. · Journal of Clinical Oncology · 2020 · 28 citations

Medicine, Oncology, Pharmacotherapy +16

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Mark N. Stein, Armelle Vinceneux, Debbie Robbrecht et al. · Journal of Clinical Oncology · 2025 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

Renal Effects of Antisense-Mediated Inhibition of SGLT2

Leonie van Meer, Matthijs Moerland, Marloes van Dongen et al. · Journal of Pharmacology and Experimental Therapeutics · 2016 · 22 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Single-Agent Divarasib in Patients With <i>KRAS G12C</i> –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study

Adrian G. Sacher, Wilson H. Miller, Manish R. Patel et al. · Journal of Clinical Oncology · 2025 · 21 citations · Full text

Medicine, Oncology, Pharmacology +16

Novel SGLT2 inhibitor: first-in-man studies of antisense compound is associated with unexpected renal effects

Leonie van Meer, Marloes van Dongen, Matthijs Moerland et al. · Pharmacology Research & Perspectives · 2017 · 15 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16